3-(2-fluoro-4-iodo-phenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid (2-hydroxy-ethoxy)-amide | 1030381-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 3-(2-fluoro-4-iodo-phenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid (2-hydroxy-ethoxy)-amide
• 英文别名: 3-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1-methylpyrrolo[3,2-c]pyridine-2-carboxamide
• CAS: 1030381-11-3
• 化学式: C₁₇H₁₆FIN₄O₃
• 分子量: 470.242
• InChiKey: CWHKAAPNEVYXJA-UHFFFAOYSA-N

物化性质

• 密度：
  1.76±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  88.4
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-(2-fluoro-4-iodo-phenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid (2-vinyloxy-ethoxy)-amide 在 盐酸 、 水 、 碳酸氢钠 作用下， 以 甲醇 为溶剂， 反应 20.17h， 以27%的产率得到3-(2-fluoro-4-iodo-phenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid (2-hydroxy-ethoxy)-amide
  参考文献：
  名称：

  WO2008/67481

  摘要：

  公开号：

文献信息

• AZA-INDOLYL COMPOUNDS AND METHODS OF USE
  申请人：Goodacre Simon Charles

  公开号：US20080242655A1

  公开（公告）日：2008-10-02

  The invention relates to azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及具有抗癌和/或抗炎活性的Formula I的吡唑吲哚类化合物，更具体地涉及抑制MEK激酶活性的吡唑吲哚类化合物。本发明提供了用于抑制异常细胞生长或治疗哺乳动物的增生性疾病或治疗炎症性疾病的组合物和方法。本发明还涉及使用该化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• Aza-indolyl compounds and methods of use
  申请人：Genentech, Inc.

  公开号：US07855216B2

  公开（公告）日：2010-12-21

  The invention relates to azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及具有抗癌和/或抗炎活性的Formula I的吡唑吲哚类化合物，更具体地涉及抑制MEK激酶活性的吡唑吲哚类化合物。本发明提供了用于抑制异常细胞生长或治疗哺乳动物的增殖性疾病或治疗炎症性疾病的组合物和方法。本发明还涉及使用该化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• Fused heteroaromatic-aniline compounds for treatment of dermal disorders
  申请人：Nflection Therapeutics, Inc.

  公开号：US10988483B2

  公开（公告）日：2021-04-27

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.

  本文提供了化合物、包含这些化合物的药物组合物、制备这些化合物的方法以及使用这些化合物和组合物治疗受试者疾病或失调的方法，其中受试者需要 MEK 的抑制剂，其中化合物根据式 (I)，其中 X、R1、R2、R2a、R3、R3a 和 R3b 如本文所述。
• Pyrrolopyridine-aniline compounds for treatment of dermal disorders
  申请人：Nflection Therapeutics, Inc.

  公开号：US11161845B2

  公开（公告）日：2021-11-02

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.

  本文提供了化合物、包含该化合物的药物组合物、制备该化合物的方法以及使用该化合物和组合物治疗受试者疾病或失调的方法，其中受试者需要 MEK 的抑制剂，其中化合物根据式 (I)，其中 X1、R1、R2、R2a、R3、R3a 和 R3b 如本文所述。
• PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
  申请人：Nflection Therapeutics, Inc.

  公开号：US20200165243A1

  公开（公告）日：2020-05-28

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X 1 , R 1 , R 2 , R 2a , R 3 , R 3a and R 3b are as described herein.